Limits...
Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.

Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L - PLoS ONE (2015)

Bottom Line: The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75).Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90).The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

ABSTRACT

Background: The prognostic value of circulating tumor cells (CTCs) in ovarian cancer has been investigated in previous studies, but the results are controversial. Therefore we performed a meta-analysis to systematically review these data and evaluate the value of CTCs in ovarian cancer.

Materials and methods: A literary search for relevant studies was performed on Embase, Medline and Web of Science databases. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analyses, sensitivity analyses, meta-regression analyses and publication bias were conducted.

Results: This meta-analysis is based on 11 publications and comprises a total of 1129 patients. The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75). Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90). The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

Conclusion: Our study demonstrates that CTC status is associated with OS and PFS/DFS in ovarian cancer.

No MeSH data available.


Related in: MedlinePlus

Forest plot showing the meta-analysis of hazard ratio estimates for OS in “Surgery” subgroup and “Chemotherapy” subgroup.Subgroup analysis based on different treatment methods. OS = overall survival.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476582&req=5

pone.0130873.g004: Forest plot showing the meta-analysis of hazard ratio estimates for OS in “Surgery” subgroup and “Chemotherapy” subgroup.Subgroup analysis based on different treatment methods. OS = overall survival.

Mentions: When it comes to the CTC detection methods, patients present with CTC showed a significantly increased risk of mortality in the "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34–3.03; Fig 3), whereas it was not significant in the "CellSearch" subgroup (HR, 1.15; 95% CI 0.45–2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62–1.90). Statistical heterogeneity was not found in "RT-PCR" subgroup, "CellSearch" subgroup and "other ICC" subgroup (I2 = 46.7%, P = 0.131; I2 = 42.9%, P = 0.186 and I2 = 0.0%, P = 0.771, respectively). In addition, we also investigated the prognostic value of CTCs for patients who received different treatment methods. Patients received chemotherapy alone in two studies and surgery (surgery alone or surgery and chemotherapy) in the other eight studies. The results showed the prognostic value of CTCs for OS was significant in the "Surgery" subgroup (HR, 1.70; 95% CI, 1.23–2.36; Fig 4) and it was not significant in the "Chemotherapy" subgroup (HR, 1.15; 95% CI 0.45–2.92). Statistical heterogeneity was not found in both "Surgery" subgroup and "Chemotherapy" subgroup (I2 = 28.8%, P = 0.199 and I2 = 42.9%, P = 0.186, respectively).


Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.

Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L - PLoS ONE (2015)

Forest plot showing the meta-analysis of hazard ratio estimates for OS in “Surgery” subgroup and “Chemotherapy” subgroup.Subgroup analysis based on different treatment methods. OS = overall survival.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476582&req=5

pone.0130873.g004: Forest plot showing the meta-analysis of hazard ratio estimates for OS in “Surgery” subgroup and “Chemotherapy” subgroup.Subgroup analysis based on different treatment methods. OS = overall survival.
Mentions: When it comes to the CTC detection methods, patients present with CTC showed a significantly increased risk of mortality in the "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34–3.03; Fig 3), whereas it was not significant in the "CellSearch" subgroup (HR, 1.15; 95% CI 0.45–2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62–1.90). Statistical heterogeneity was not found in "RT-PCR" subgroup, "CellSearch" subgroup and "other ICC" subgroup (I2 = 46.7%, P = 0.131; I2 = 42.9%, P = 0.186 and I2 = 0.0%, P = 0.771, respectively). In addition, we also investigated the prognostic value of CTCs for patients who received different treatment methods. Patients received chemotherapy alone in two studies and surgery (surgery alone or surgery and chemotherapy) in the other eight studies. The results showed the prognostic value of CTCs for OS was significant in the "Surgery" subgroup (HR, 1.70; 95% CI, 1.23–2.36; Fig 4) and it was not significant in the "Chemotherapy" subgroup (HR, 1.15; 95% CI 0.45–2.92). Statistical heterogeneity was not found in both "Surgery" subgroup and "Chemotherapy" subgroup (I2 = 28.8%, P = 0.199 and I2 = 42.9%, P = 0.186, respectively).

Bottom Line: The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75).Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90).The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Laboratory, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

ABSTRACT

Background: The prognostic value of circulating tumor cells (CTCs) in ovarian cancer has been investigated in previous studies, but the results are controversial. Therefore we performed a meta-analysis to systematically review these data and evaluate the value of CTCs in ovarian cancer.

Materials and methods: A literary search for relevant studies was performed on Embase, Medline and Web of Science databases. Then pooled hazard ratios (HRs) for survival with 95% confidence intervals (CIs), subgroup analyses, sensitivity analyses, meta-regression analyses and publication bias were conducted.

Results: This meta-analysis is based on 11 publications and comprises a total of 1129 patients. The prognostic value of the CTC status was significant in overall survival (OS) (HR, 1.61;95% CI,1.22-2.13) and progression-free survival (PFS)/disease-free survival (DFS) (HR, 1.44; 95%CI, 1.18-1.75). Furthermore, subgroup analysis revealed that the value of CTC status in OS was significant in "RT-PCR" subgroup (HR, 2.02; 95% CI, 1.34-3.03), whereas it was not significant in "CellSearch" subgroup (HR, 1.15; 95% CI 0.45-2.92) and "other ICC" subgroup (HR, 1.09; 95% CI 0.62-1.90). The presence of CTC was also associated with an increased CA-125 (OR, 4.07; 95%CI, 1.87-8.85).

Conclusion: Our study demonstrates that CTC status is associated with OS and PFS/DFS in ovarian cancer.

No MeSH data available.


Related in: MedlinePlus